Immuneering (IMRX)
(Delayed Data from NSDQ)
$1.20 USD
+0.09 (8.11%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $1.20 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
IMRX 1.20 +0.09(8.11%)
Will IMRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IMRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMRX
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet
IMRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates
Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last?
Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?
Other News for IMRX
12 Health Care Stocks Moving In Tuesday's After-Market Session
Immuneering to Present at the Jefferies Global Healthcare Conference
Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment
Buy Rating Affirmed for Immuneering with $8 Price Target Amidst Promising Pipeline and Upcoming Data Events
Oppenheimer Keeps Their Buy Rating on Immuneering (IMRX)